There is no optimal treatment for lupus erythematosus nephritis type IV. Treatment options vary from person to person and include immunosuppressive therapy, supportive therapy for associated manifestations and complications. Lupus nephritis is active and inactive, with diffuse (involved glomeruli equal to or greater than 50%) segmental or globular distribution, intracapillary or extracapillary proliferative lesions, with diffuse subendothelial immune complex deposition, with or without mesangial proliferative lesions. 1. Immunosuppressive therapy: the evaluation of the effect of an immunotherapy should include two aspects, the induced remission rate in the active phase and the effect on the long-term prognosis of renal function. Immunosuppressive therapeutic agents include hormones (prednisone and methylprednisolone), cyclophosphamide, cyclosporine, and hydroxychloroquine. If there is no contraindication for lupus nephritis, hydroxychloroquine treatment should be added to all patients. 2. Lupus nephritis belongs to the category of chronic kidney disease, and the supportive treatment should follow the principle of “integration”, such as strictly controlling hypertension, hyperlipidemia, adjusting calcium and phosphorus metabolism, etc., which should pay special attention to the control of cardiovascular disease risk factors. Patients with lupus erythematosus nephritis type IV should go to the hospital in time, and individualized treatment plan should be made under the guidance of professional doctors.